Advanced Proteome Therapeutics (Advanced Proteome Therapeutics) Net Issuance of Preferred Stock : $0.00 Mil (TTM As of Apr. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Advanced Proteome Therapeutics Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Advanced Proteome Therapeutics's net issuance of preferred for the three months ended in Apr. 2023 was $0.00 Mil. The number is 0, which means that Advanced Proteome Therapeutics has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Advanced Proteome Therapeutics's net issuance of preferred for the trailing twelve months (TTM) ended in Apr. 2023 was $0.00 Mil.

Advanced Proteome Therapeutics Net Issuance of Preferred Stock Historical Data

The historical data trend for Advanced Proteome Therapeutics's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advanced Proteome Therapeutics Net Issuance of Preferred Stock Chart

Advanced Proteome Therapeutics Annual Data

Trend

Jul13

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Net Issuance of Preferred Stock

Get a 7-Day Free Trial

Advanced Proteome Therapeutics Quarterly Data
	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23
Net Issuance of Preferred Stock	Get a 7-Day Free Trial															-	-	-	-	-

Advanced Proteome Therapeutics Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Apr. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Advanced Proteome Therapeutics Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Advanced Proteome Therapeutics's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Advanced Proteome Therapeutics (Advanced Proteome Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advanced Proteome Therapeutics Corp (OTCPK:APTCF) » Definitions » Net Issuance of Preferred Stock

Comparable Companies

Traded in Other Exchanges

0E81:Germany APC.H:Canada

Address

8337 Eastlake Drive, Suite 104, Burnaby, BC, CAN, V5A 4W2

Website

https://www.advancedproteome.com

Advanced Proteome Therapeutics Corp is a biotechnology company. It develops and commercializes a platform to use protein modification technologies to create proprietary human protein pharmaceuticals with therapeutic properties. The company develops anti-cancer drugs for cancerous tumors that will destroy a cancer patient's tumor cells selectively, sparing healthy cells. All the operations of the organization are principally carried out in the United States.

Advanced Proteome Therapeutics (Advanced Proteome Therapeutics) Headlines

From GuruFocus

Advanced Proteome Therapeutics Announces Closing of First Tranche of a Non-Brokered Private Placement

By GlobeNewswire GlobeNewswire • 08-23-2018

Advanced Proteome Therapeutics Announces Appointment of Bill Dickie as Chief Executive Officer, President and Director

By GlobeNewswire GlobeNewswire • 06-06-2018